Loading patent…
AssigneesThe University of Western Ontario, Stanford University
InventorsGregory A. Dekaban, Jacqueline Arp, Steven Kok Hing Foung
Estimating the term…
Isolated and purified envelope protein of HTLV-I is provided devoid of non-envelope protein of HTLV-I and having substantially the same conformation as the envelope protein in native HTLV-I. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Non-glycosylated and glycosylated forms of the protein are produced. Glycosylated forms are recognized by antibodies specific for the envelope protein of HTLV-I. Monoclonal antibodies are provided which are specific for the HTLV-I envelope protein and non-binding to HTLV-I envelope protein in denatured form. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV. The envelope protein is useful in diagnosis of infection by HTLV-I and HTLV-II.
An isolated and purified envelope protein of Human T-cell Lymphotrophic Virus Type I (HTLV-I) devoid of nonenvelope proteins of HTLV-1 having substantially the same conformation as the envelope protein in native HTLV-I, wherein said protein is in a glycosylated form and has an apparent molecular weight as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of about 47 to about 49 kDa.
A protein mixture of at least two isolated and purified envelope proteins of HTLV-I devoid of non-envelope proteins of HTLV-1 having an apparent molecular weight which is selected from about 45 kDa, about 47 kDa and about 49 kDa, as determined by sodium dodecy 1 sulfate polyacrylamide gel electrophoresis.
An isolated and purified envelope glycosylated protein of HTLV-I devoid of non-envelope proteins of HTLV-I which has an apparent molecular weight as determined by SDS-PAGE of about 47 to about 49 kDa and which is recognized by an antibody, specific for the envelope protein of Human T-cell Lymphotrophic Virus Type II.
Dependencies are inferred from the claim text.